CSNK1A1 and leukemia: pyrvinium targets solid (e.g., prostate and breast) and blood (e.g., myeloma and leukemia) cancers via three main mechanisms: (i) Wnt–β-catenin pathway suppression; (ii) CK1α activation; and (iii) mitochondrial respiration inhibition (18).